Navigation Links
NanoBio Corporation Announces Positive Phase 1 Clinical Results for,Topical Treatment for Onychomycosis

ANN ARBOR, Mich., May 22, 2007 /PRNewswire/ -- NanoBio Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of serious infections, today announced positive safety data from its Phase 1 clinical study of NB-002, the company's drug candidate currently in a Phase 2 clinical trial for the topical treatment of onychomycosis.

The Phase 1 clinical study was completed in January 2007 and involved 20 subjects who received twice-daily treatments of NB-002 (0.25% or 0.5%) for 28 days. Subjects were examined on days 1, 3, 7, 14, 28 and 58 for adverse events, dermal irritation and pharmacokinetic sampling. There were no drug- related adverse events, serious adverse events or discontinuations due to adverse events in any of the subjects treated. In addition, plasma drug levels were below the limit of detection (1 ng/mL) at all time points. Based on the remarkable safety profile demonstrated in this clinical study as well as other previously conducted clinical and toxicology studies, a 42-week double-blinded Phase 2 clinical study of NB-002 was initiated by NanoBio in the first quarter of 2007.

James R. Baker, MD, NanoBio's Chairman of the Board and Chief Science Officer, commented, "A unique aspect of products derived from the company's NanoStat(TM) technology is that the treatments are not systemically absorbed and they are selectively toxic to microbes while non-irritating to the skin and mucous membranes. This Phase 1 safety data further confirms that NB-002 will offer a safe alternative to the currently available systemic products. This is a critical factor for individuals affected by onychomycosis, given approximately 95% of people with this disease remain untreated as a result of the serious toxicities associated with the oral medications on the market."

Phase 2 Clinical Study for NB-002

A randomized, double-blinded, placebo-controlled Phase 2 c
'"/>




Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
3. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
4. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:10/8/2008)...NDRIA, Va., Oct. 8 /PRNewswire-USNewswire/ -- The ...ople die from HIV/AIDS in,sub-Saharan Africa. More...aharan Africa have already died of AIDS. The Found...g to ensure the dying and their families,find comp...e. FHSSA,s,innovative partnering initiative links ...
(Date:10/8/2008)...anolimumab Program to be Discontinued and Headcoun...ults of its Portfolio Review; Zanolimumab Program...e Number of Employee...- Genmab A/S (OMX: GEN),announced today that it is...D4(R)). In addition, as a result of a portfolio re...
(Date:10/8/2008)... France, Oct. 8 /- Vical Incorporated...nical data and new nonclinical data,demonstrating ...oadly,applicable in DNA- and protein-based infecti...ines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,S...present the data today,Wednesday, October 8, at t...
(Date:10/7/2008)...luates the efficacy of new device for detecting po...ng colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswire...nnual Scientific Meeting in Orlando (ACG 2008), re...nted results from a,multi-institutional clinical s...R) Retroscope(R), a new device that is designed to...
Breaking Medicine Technology:In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Doctors Often Fail to Spot Suicidal Patients 1926 1Doctors Often Fail to Spot Suicidal Patients 1926 2Doctors Often Fail to Spot Suicidal Patients 1926 3Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 1Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 2USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 1USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 2SalesForce4Hire Opens New Office 1920 1SalesForce4Hire Opens New Office 1920 2
...wire-FirstCall/ -- Shire plc ,the market leader i...isorder (ADHD), announced that it will present key...t the American Psychiatric,Association (APA) annua..."The upcoming clinical research to be presented at... the science of ADHD treatment,",said Eliseo Salin...
...5, 2007 - Gemin X Biotechnologies,Inc. announced t...demonstrated that its lead compound, obatoclax (GX...l Lymphoma (MCL) cell lines and,primary cells from...molecule specifically designed to inhibit all rele...ted cancer target, thus restoring,the natural cell...
Other Medicine Technology:Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 2Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 3Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 4Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 5Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 6Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 7Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...1 or juvenile-onset diabetes also works in a rat m...g to a new report from researchers at Washington U...g that we can cure type 2 diabetes in the same way... type 2 diabetes is almost 20 times more prevalent...
...es the establishment of the Center for Celiac Dise...ose//, treat and provide support for patients and ...ac disease is unable to digest gluten, a common in...g bread, pasta and even condiments,” said Ritu Ver...
...hydrate molecules so as to prepare for an invasion...of Florida, which has been published in the curren...not only humans but viruses too that crave for car...ed that the viruses hang on to the carbohydrates t...
...f Adults Cannot Manage Without Cell Phones.The res...shire in Stoke-on-Trent, who had conducted the res...ictive behavior when it comes to their cell phones...mobile phones, he observed that some of the behavi...
Other Medicine News:Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 2Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 3Health News:Center for Celiac Disease Opens 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 3
Introducing the new Platinum 10 concentrator. The Platinum 10 delivers the reliability, performance and value advantage you have come to expect from the Platinum line of concentrators and provides an
...table Oxygen Concentrator is the most compact, lig...than 10 lbs (4.5 kg), this unit was designed to ac...e oxygen patient., ,Operating as a pulse flow... oxygen concentrator and an oxygen conserver in on...
OCD-3000 pnuematic conserving regulator.
...7.5 liters out of your five-liter concentrators. ,...igh-flow patients! , ,In many ways, the OXYMIZER...e standard conservers, because they extend oxygen ...o saturate a patient. However, they do not requir...
Medicine Products: